Drugs targeting SARS-CoV-2 could have saved millions of lives during the COVID-19
pandemic, and it is now crucial to develop inhibitors of coronavirus replication in
preparation for future outbreaks. We explored two virtual screening strategies to find
inhibitors of the SARS-CoV-2 main protease in ultralarge chemical libraries. First,
structure-based docking was used to screen a diverse library of 235 million virtual
compounds against the active site. One hundred top-ranked compounds were tested in
binding and enzymatic assays. Second, a fragment discovered by crystallographic
screening was optimized guided by docking of millions of elaborated molecules and
experimental testing of 93 compounds. Three inhibitors were identified in the first
library screen, and five of the selected fragment elaborations showed inhibitory
effects. Crystal structures of target–inhibitor complexes confirmed docking
predictions and guided hit-to-lead optimization, resulting in a noncovalent main
protease inhibitor with nanomolar affinity, a promising in vitro pharmacokinetic
profile, and broad-spectrum antiviral effect in infected cells.